Summary:
In type 2 diabetic patients undergoing laparoscopic colorectal cancer radical resection, dexmedetomidine (loading dose 1 μg/kg and maintenance dose 0.25 μg/kg/h) significantly improved perioperative blood glucose regulation compared to control group without dexmedetomidine, though it was associated with no increase in perioperative hyperglycemia, adverse effects, or extubation time.
| PICO | Description |
|---|---|
| Population | Type 2 diabetic patients undergoing laparoscopic colorectal cancer radical resection. |
| Intervention | Dexmedetomidine administered as a loading dose of 1 μg/kg followed by a maintenance infusion at 0.25 μg/kg/h during the perioperative period. |
| Comparison | Control group without dexmedetomidine administration during perioperative period. |
| Outcome | Dexmedetomidine significantly improved blood glucose regulation perioperatively without increasing the incidence of hyperglycemia, adverse events, or lengthening extubation time. |
Source: Wei Dai, et al. “Effect of dexmedetomidine on perioperative blood glucose regulation in type 2 diabetic patients undergoing laparoscopic colorectal cancer radical resection: a randomised double-blinded controlled trial.” Read article here.
